Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Supportan returned no results
Showing 166 to 180 of 747 results for supported

  1. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)

    Evidence-based recommendations on imatinib (Glivec) for treating gastrointestinal stromal tumours in adults.

  2. UrgoStart for treating diabetic foot ulcers and leg ulcers (HTG502)

    Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.

  3. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes (NG5)

    This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.

  4. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)

    Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.

  5. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

    Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.

  6. Home care for older people (QS123)

    This quality standard covers care and support for older people living in their own homes (known as home care or domiciliary care). It covers people aged over 65 using home care services, and may also cover some people under 65 with complex needs. It describes high-quality care in priority areas for improvement.

  7. The geko device for reducing the risk of venous thromboembolism (HTG344)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.

  8. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.

  9. Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)

    Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy.

  10. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

  11. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.

  12. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  13. Hepatitis B and C testing: people at risk of infection (PH43)

    This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

  14. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  15. Antimicrobial prescribing: meropenem with vaborbactam (ES21)

    Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making